Melphalan and its role in the management of patients with multiple myeloma

被引:47
作者
Falco, Patrizia [1 ]
Bringhen, Sara [1 ]
Avonto, Ilaria [1 ]
Gay, Francesca [1 ]
Morabito, Fortunato [1 ]
Boccadoro, Mario [1 ]
Palumbo, Antonio [1 ]
机构
[1] Univ Turin, Div Ematol, Azienda Osped San Giovanni Battista, I-10126 Turin, Italy
关键词
combination therapy; melphalan; multiple myeloma; transplant;
D O I
10.1586/14737140.7.7.945
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Melphalan is an alkylating agent approved for the treatment of multiple myeloma and ovarian cancer. The combination of oral melphalan and prednisone was first introduced in the 1960s and remains the standard therapy for elderly multiple myeloma patients. High-dose melphalan followed by autologous stem cell support became the standard treatment for younger patients since the 1990s. The occurrence of drug resistance is the major limiting factor for the long-term success of this therapy, and relapse always occurs. In recent years, advances in the understanding of the pathogenesis of myeloma and the mechanism of drug resistance have led to the development of novel targeted therapies that are able to overcome resistance and show additive or synergistic effects with melphalan. Thalidomide, its immunomodulatory derivative lenalidomide and the proteasome inhibitor bortezomib, in combination with oral melphalan in the elderly and with intravenous melphalan in younger patients, are changing the traditional treatment paradigm of multiple myeloma.
引用
收藏
页码:945 / 957
页数:13
相关论文
共 88 条
[1]  
ADAIR CG, 1988, CANCER CHEMOTH PHARM, V22, P348
[2]  
ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P737
[3]   TREATMENT FOR MULTIPLE MYELOMA - COMBINATION CHEMOTHERAPY WITH DIFFERENT MELPHALAN DOSE REGIMENS [J].
ALEXANIAN, R ;
HAUT, A ;
KHAN, AU ;
LANE, M ;
MCKELVEY, EM ;
MIGLIORE, PJ ;
STUCKEY, WJ ;
WILSON, HE .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 208 (09) :1680-+
[4]   VAD-BASED REGIMENS AS PRIMARY-TREATMENT FOR MULTIPLE-MYELOMA [J].
ALEXANIAN, R ;
BARLOGIE, B ;
TUCKER, S .
AMERICAN JOURNAL OF HEMATOLOGY, 1990, 33 (02) :86-89
[5]  
ALEXANIAN R, 1990, ARCH INTERN MED, V150, P1693
[6]   Single versus double autologous stem-cell transplantation for multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Facon, T ;
Guilhot, F ;
Doyen, C ;
Fuzibet, JG ;
Monconduit, M ;
Hulin, C ;
Caillot, D ;
Bouabdallah, R ;
Voillat, L ;
Sotto, JJ ;
Grosbois, B ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502
[7]   A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].
Attal, M ;
Harousseau, JL ;
Stoppa, AM ;
Sotto, JJ ;
Fuzibet, JG ;
Rossi, JF ;
Casassus, P ;
Maisonneuve, H ;
Facon, T ;
Ifrah, N ;
Payen, C ;
Bataille, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97
[8]   Maintenance, therapy with thalidomide improves survival in patients with multiple myeloma [J].
Attal, Michel ;
Harousseau, Jean-Luc ;
Leyvraz, Serge ;
Doyen, Chantal ;
Hulin, Cyrille ;
Benboubker, Lofti ;
Agha, Ibrahim Yakoub ;
Bourhis, Jean-Henri ;
Garderet, Laurent ;
Pegourie, Brigitte ;
Dumontet, Charles ;
Renaud, Marc ;
Voillat, Laurent ;
Berthou, Christian ;
Marit, Gerald ;
Monconduit, Mathieu ;
Caillot, Denis ;
Grobois, Bernard ;
Avet-Loiseau, Herve ;
Moreau, Philippe ;
Facon, Thierry .
BLOOD, 2006, 108 (10) :3289-3294
[9]   Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years [J].
Badros, A ;
Barlogie, B ;
Siegel, E ;
Morris, C ;
Desikan, R ;
Zangari, M ;
Fassas, A ;
Anaissie, E ;
Munshi, N ;
Tricot, G .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (03) :600-607
[10]  
BADROS A, 2001, BRIT J HAEMATOL, V12, P651